Geroscience and Alzheimer’s Disease Drug Development

Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease. Lancet. 2021;S0140-6736(20):32205–4. doi: https://doi.org/10.1016/S0140-6736(20)32205-4. Jack CR, Jr., Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62. doi: https://doi.org/10.1016/j.jalz.2018.02.018. Thakur S, Dhapola R, Sarma P, Medhi B, Reddy DH. Neuroinflammation in Alzheimer’s disease: current progress in molecular signaling and therapeutics. Inflammation. 2023;46(1):1–17. doi: https://doi.org/10.1007/s10753-022-01721-1. Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691–704. doi: https://doi.org/10.1056/NEJMoa2100708. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2022. doi: https://doi.org/10.1056/NEJMoa2212948. Esposto J, Balendara V. Brief about hallmarks of aging. In: Singh SK, Lin C, Mishra SK, editors. Anti-aging Drug Discovery on the Basis of Hallmarks of Aging. United Kingdom: Academic Press; 2022. p. 41–60. Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159(4):709–13. doi: https://doi.org/10.1016/j.cell.2014.10.039. Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518–36. doi: https://doi.org/10.1111/joim.13141. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–217. doi: https://doi.org/10.1016/j.cell.2013.05.039. Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer’s disease drug development pipeline: 2023. Alzheimers Dement (N Y). 2023;9(2):e12385. doi: https://doi.org/10.1002/trc2.12385. Sierra F. The emergence of geroscience as an interdisciplinary approach to the enhancement of health span and life span. Cold Spring Harb Perspect Med. 2016;6(4):a025163. doi: https://doi.org/10.1101/cshperspect.a025163. Sierra F, Caspi A, Fortinsky RH, et al. Moving geroscience from the bench to clinical care and health policy. J Am Geriatr Soc. 2021;69(9):2455–63. doi: https://doi.org/10.1111/jgs.17301. Schubert D, Currais A, Goldberg J, Finley K, Petrascheck M, Maher P. Geroneuroprotectors: effective geroprotectors for the brain. Trends Pharmacol Sci. 2018;39(12):1004–7. doi: https://doi.org/10.1016/j.tips.2018.09.008. Kepchia D, Currais A, Dargusch R, Finley K, Schubert D, Maher P. Geroprotective effects of Alzheimer’s disease drug candidates. Aging (Albany NY). 2021;13(3):3269–89. doi: https://doi.org/10.18632/aging.202631. Pitkala KH, Strandberg TE. Clinical trials in older people. Age Ageing. 2022;51(5). doi: https://doi.org/10.1093/ageing/afab282. Banzi R, Camaioni P, Tettamanti M, Bertele V, Lucca U. Older patients are still under-represented in clinical trials of Alzheimer’s disease. Alzheimers Res Ther. 2016;8:32. doi: https://doi.org/10.1186/s13195-016-0201-2. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576–90. doi: https://doi.org/10.1038/s41574-018-0059-4. Fulop T, Larbi A, Pawelec G, et al. Immunology of aging: the birth of inflammaging. Clin Rev Allergy Immunol. 2023;64(2):109–22. doi: https://doi.org/10.1007/s12016-021-08899-6. Robbins PD, Jurk D, Khosla S, et al. Senolytic drugs: reducing senescent cell viability to extend health span. Annu Rev Pharmacol Toxicol. 2021;61:779–803. doi: https://doi.org/10.1146/annurev-pharmtox-050120-105018. Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246–56. doi: https://doi.org/10.1038/s41591-018-0092-9. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18–28. doi: https://doi.org/10.1016/j.ebiom.2018.09.015. Kulkarni AS, Gubbi S, Barzilai N. Benefits of metformin in attenuating the hallmarks of aging. Cell Metab. 2020;32(1):15–30. doi: https://doi.org/10.1016/j.cmet.2020.04.001. Chen S, Gan D, Lin S, et al. Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms. Theranostics. 2022;12(6):2722–40. doi: https://doi.org/10.7150/thno.71360. Niedernhofer LJ, Kirkland JL, Ladiges W. Molecular pathology endpoints useful for aging studies. Ageing Res Rev. 2017;35:241–9. doi: https://doi.org/10.1016/j.arr.2016.09.012. Justice JN, Ferrucci L, Newman AB, et al. A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup. Geroscience. 2018;40(5–6):419–36. doi: https://doi.org/10.1007/s11357-018-0042-y. Liguori I, Russo G, Curcio F, et al. Oxidative stress, aging, and diseases. Clin Interv Aging. 2018;13:757–72. doi: https://doi.org/10.2147/CIA.S158513. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med. 1997;336(17):1216–22. doi: https://doi.org/10.1056/NEJM199704243361704. Jong CJ, Sandal P, Schaffer SW. The role of taurine in mitochondria health: more than just an antioxidant. Molecules. 2021;26(16). doi: https://doi.org/10.3390/molecules26164913. Hey JA, Yu JY, Versavel M, et al. Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer’s disease. Clin Pharmacokinet. 2018;57(3):315–33. doi: https://doi.org/10.1007/s40262-017-0608-3. Selvarani R, Mohammed S, Richardson A. Effect of rapamycin on aging and age-related diseases-past and future. Geroscience. 2021;43(3):1135–58. doi: https://doi.org/10.1007/s11357-020-00274-1. Halloran J, Hussong SA, Burbank R, et al. Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience. 2012;223:102–13. doi: https://doi.org/10.1016/j.neuroscience.2012.06.054. Pal S, Tyler JK. Epigenetics and aging. Sci Adv. 2016;2(7):e1600584. doi: https://doi.org/10.1126/sciadv.1600584. Watroba M, Szukiewicz D. Sirtuins at the service of healthy longevity. Front Physiol. 2021;12:724506. doi: https://doi.org/10.3389/fphys.2021.724506. Kida Y, Goligorsky MS. Sirtuins, cell senescence, and vascular aging. Can J Cardiol. 2016;32(5):634–41. doi: https://doi.org/10.1016/j.cjca.2015.11.022. Jesko H, Wencel P, Strosznajder RP, Strosznajder JB. Sirtuins and their roles in brain aging and neurodegenerative disorders. Neurochem Res. 2017;42(3):876–90. doi: https://doi.org/10.1007/s11064-016-2110-y. Fernando KKM, Wijayasinghe YS. Sirtuins as potential therapeutic targets for mitigating neuroinflammation associated with Alzheimer’s disease. Front Cell Neurosci. 2021;15:746631. doi: https://doi.org/10.3389/fncel.2021.746631. Ungurianu A, Zanfirescu A, Margina D. Sirtuins, resveratrol and the intertwining cellular pathways connecting them. Ageing Res Rev. 2023;88:101936. doi: https://doi.org/10.1016/j.arr.2023.101936. Turner RS, Thomas RG, Craft S, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85(16):1383–91. doi: https://doi.org/10.1212/WNL.0000000000002035. Tsujikawa LM, Fu L, Das S, et al. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism. Clin Epigenetics. 2019;11(1):102. doi: https://doi.org/10.1186/s13148-019-0696-z. Cummings J, Schwartz GG, Nicholls SJ, et al. Cognitive effects of the BET protein inhibitor apabetalone: a prespecified Montreal Cognitive Assessment analysis nested in the BETonMACE randomized controlled trial. J Alzheimers Dis. 2021;83(4):1703–15. doi: https://doi.org/10.3233/JAD-210570. Chakravarti D, LaBella KA, DePinho RA. Telomeres: history, health, and hallmarks of aging. Cell. 2021;184(2):306–22. doi: https://doi.org/10.1016/j.cell.2020.12.028. Koh SH, Kwon HS, Choi SH, et al. Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. Alzheimers Res Ther. 2021;13(1):66. doi: https://doi.org/10.1186/s13195-021-00803-w. van den Beld AW, Kaufman JM, Zillikens MC, Lamberts SWJ, Egan JM, van der Lely AJ. The physiology of endocrine systems with ageing. Lancet Diabetes Endocrinol. 2018;6(8):647–58. doi: https://doi.org/10.1016/S2213-8587(18)30026-3. Scheyer O, Rahman A, Hristov H, et al. Female sex and Alzheimer’s risk: the menopause connection. J Prev Alzheimers Dis. 2018;5(4):225–30. doi: https://doi.org/10.14283/jpad.2018.34. Henderson VW. Alzheimer’s disease: review of hormone therapy trials and implications for treatment and prevention after menopause. J Steroid Biochem Mol Biol. 2014;142:99–106. doi: https://doi.org/10.1016/j.jsbmb.2013.05.010. Xiong J, Kang SS, Wang Z, et al. FSH blockade improves cognition in mice with Alzheimer’s disease. Nature. 2022;603(7901):470–6. doi: https://doi.org/10.1038/s41586-022-04463-0. Lu PH, Masterman DA, Mulnard R, et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol. 2006;63(2):177–85. doi: https://doi.org/10.1001/archneur.63.2.nct50002. Middeldorp J, Lehallier B, Villeda SA, et al. Preclinical assessment of young blood plasma for Alzheimer disease. JAMA Neurol. 2016;73(11):1325–33. doi: https://doi.org/10.1001/jamaneurol.2016.3185. Sha SJ, Deutsch GK, Tian L, et al. Safety, tolerability, and feasibility of young plasma infusion in the plasma for Alzheimer symptom amelioration study: a randomized clinical trial. JAMA Neurol. 2019;76(1):35–40. doi: https://doi.org/10.1001/jamaneurol.2018.3288. Boada M, Lopez OL, Olazaran J, et al. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer’s disease: Primary results of the AMBAR Study. Alzheimers Dement. 2020;16(10):1412–25. doi: https://doi.org/10.1002/alz.12137. Boada M, Martinez-Lage P, Serrano-Castro P, Costa M, Paez A. Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer’s disease. Expert Rev Neurother. 2021;21(8):843–9. doi: https://doi.org/10.1080/14737175.2021.1960823. Brunet A, Goodell MA, Rando TA. Ageing and rejuvenation of tissue stem cells and their niches. Nat Rev Mol Cell Biol. 2023;24(1):45–62. doi: https://doi.org/10.1038/s41580-022-00510-w. Hu J, Wang X. Alzheimer’s disease: from pathogenesis to mesenchymal stem cell therapy - bridging the missing link. Front Cell Neurosci. 2021;15:811852. doi: https://doi.org/10.3389/fncel.2021.811852. Tompkins BA, DiFede DL, Khan A, et al. Allogeneic mesenchymal stem cells ameliorate aging frailty: a phase II randomized, double-blind, placebo-controlled clinical trial. J Gerontol A Biol Sci Med Sci. 2017;72(11):1513–22. doi: https://doi.org/10.1093/gerona/glx137. Brody M, Agronin M, Herskowitz BJ, et al. Results and insights from a phase I clinical trial of Lomecel-B for Alzheimer’s disease. Alzheimers Dement. 2023;19(1):261–73. doi: https://doi.org/10.1002/alz.12651. Kim HJ, Cho KR, Jang H, et al. Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase I clinical trial. Alzheimers Res Ther. 2021;13(1):154. doi: https://doi.org/10.1186/s13195-021-00897-2. Clare L, Wu YT, Teale JC, et al. Potentially modifiable lifestyle factors, cognitive reserve, and cognitive function in later life: A cross-sectional study. PLoS Med. 2017;14(3):e1002259. doi: https://doi.org/10.1371/journal.pmed.1002259. Montine TJ, Cholerton BA, Corrada MM, et al. Concepts for brain aging: resistance, resilience, reserve, and compensation. Alzheimers Res Ther. 2019;11(1):22. doi: https://doi.org/10.1186/s13195-019-0479-y. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–63. doi: https://doi.org/10.1016/S0140-6736(15)60461-5. Nuzum H, Stickel A, Corona M, Zeller M, Melrose RJ, Wilkins SS. Potential benefits of physical activity in MCI and dementia. Behav Neurol. 2020;2020:7807856. doi: https://doi.org/10.1155/2020/7807856. Mahalakshmi B, Maurya N, Lee SD, Bharath Kumar V. Possible neuroprotective mechanisms of physical exercise in neurodegeneration. Int J Mol Sci. 2020;21(16). doi: https://doi.org/10.3390/ijms21165895. Ruiz-Gonzalez D, Hernandez-Martinez A, Valenzuela PL, Morales JS, Soriano-Maldonado A. Effects of physical exercise on plasma brain-derived neurotrophic factor in neurodegenerative disorders: A systematic review and meta-analysis of randomized controlled trials. Neurosci Biobehav Rev. 2021;128:394–405. doi: https://doi.org/10.1016/j.neubiorev.2021.05.025. Ackert-Bicknell CL, Anderson LC, Sheehan S, et al. Aging research using mouse models. Curr Protoc Mouse Biol. 2015;5(2):95–133. doi: https://doi.org/10.1002/9780470942390.mo140195. Whitehead JC, Hildebrand BA, Sun M, et al. A clinical frailty index in aging mice: comparisons with frailty index data in humans. J Gerontol A Biol Sci Med Sci. 2014;69(6):621–32. doi: https://doi.org/10.1093/gerona/glt136. Takeda T. Senescence-accelerated mouse (SAM) with special references to neurodegeneration models, SAMP8 and SAMP10 mice. Neurochem Res. 2009;34(4):639–59. doi: https://doi.org/10.1007/s11064-009-9922-y. Blumel L, Brosda J, Bert B, Hamann M, Dietz GPH. Moderately aged OFA rats as a novel model for mild age-related alterations in learning and memory Brain Cogn. 2021;154:105799. doi: https://doi.org/10.1016/j.bandc.2021.105799. Gocmez SS, Yazir Y, Gacar G, et al. Etanercept improves aging-induced cognitive deficits by reducing inflammation and vascular dysfunction in rats. Physiol Behav. 2020;224:113019. doi: https://doi.org/10.1016/j.physbeh.2020.113019. Miller MG, Thangthaeng N, Shukitt-Hale B. A clinically relevant frailty index for aging rats. J Gerontol A Biol Sci Med Sci. 2017;72(7):892–6. doi: https://doi.org/10.1093/gerona/glw338. Plagenhoef MR, Callahan PM, Beck WD, Blake DT, Terry AV, Jr. Aged rhesus monkeys: cognitive performance categorizations and preclinical drug testing. Neuropharmacology. 2021;187:108489. doi: https://doi.org/10.1016/j.neuropharm.2021.108489. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67–76. doi: https://doi.org/10.1080/03602530902722679. Ao G, de Miguel M, Gomes A, et al. Toxicity and antitumor activity of novel agents in elderly patients with cancer included in phase 1 studies. Invest New Drugs. 2021;39(6):1694–701. doi: https://doi.org/10.1007/s10637-021-01150-1. Buechel M, McGinnis A, Vesely SK, Wade KS, Moore KN, Gunderson CC. Consideration of older patients for enrollment in phase 1 clinical trials: Exploring treatment related toxicities and outcomes. Gynecol Oncol. 2018;149(1):28–32. doi: https://doi.org/10.1016/j.ygyno.2017.11.021. Frontzkowski L, Ewers M, Brendel M, et al. Earlier Alzheimer’s disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading. Nat Commun. 2022;13(1):4899. doi: https://doi.org/10.1038/s41467-022-32592-7. Rahimi J, Kovacs GG. Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther. 2014;6(9):82. doi: https://doi.org/10.1186/s13195-014-0082-1. Forrest SL, Kovacs GG. Current concepts of mixed pathologies in neurodegenerative diseases. Can J Neurol Sci. 2023;50(3):329–45. doi: https://doi.org/10.1017/cjn.2022.34. Patrizio E, Calvani R, Marzetti E, Cesari M. Physical functional assessment in older adults. J Frailty Aging. 2021;10(2):141–9. doi: https://doi.org/10.14283/jfa.2020.61. Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85–94. doi: https://doi.org/10.1093/geronj/49.2.m85. George PP, Lun P, Ong SP, Lim WS. A rapid review of the measurement of intrinsic capacity in older adults. J Nutr Health Aging. 2021;25(6):774–82. doi: https://doi.org/10.1007/s12603-021-1622-6. Mahoney FI, Barthel DW. Function Evaluation: The Barthel Index. Md State Med J. 1965;14:61–5. Andrew MK, Matthews S, Kim JH, Riley ME, Curran D. An easy-to-implement clinical-trial frailty index based on accumulation of eficits: validation in zoster vaccine clinical trials. Clin Interv Aging. 2022;17:1261–74. doi: https://doi.org/10.2147/CIA.S364997. Cummings J, Kinney J. Biomarkers for Alzheimer’s disease: context of use, qualification, and roadmap for clinical implementation. Medicina (Kaunas). 2022;58(7). doi: https://doi.org/10.3390/medicina58070952. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet. 2018;19(6):371–84. doi: https://doi.org/10.1038/s41576-018-0004-3. Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018;10(4):573–91. doi: https://doi.org/10.18632/aging.101414. Franceschi C, Garagnani P, Vitale G, Capri M, Salvioli S. Inflammaging and ‘Garb-aging’. Trends Endocrinol Metab. 2017;28(3):199–212. doi: https://doi.org/10.1016/j.tem.2016.09.005. Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822–32. doi: https://doi.org/10.1038/s41591-019-0675-0. Sayed N, Huang Y, Nguyen K, et al. An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging. Nat Aging. 2021;1:598–615. doi: https://doi.org/10.1038/s43587-021-00082-y. Vaiserman A, Krasnienkov D. Telomere length as a marker of biological age: state-of-the-art, open issues, and future perspectives. Front Genet. 2020;11:630186. doi: https://doi.org/10.3389/fgene.2020.630186. Kim S, Jazwinski SM. The gut microbiota and healthy aging: a mini-review. Gerontology. 2018;64(6):513–20. doi: https://doi.org/10.1159/000490615. McCarthy D, Wang PL. Mortality postponement and compression at older ages in human cohorts. PLoS One. 2023;18(3):e0281752. doi: https://doi.org/10.1371/journal.pone.0281752.